Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Understanding EGFR heterogeneity in lung cancer.
Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Passaro A, et al. Among authors: cucchiara f. ESMO Open. 2020 Oct;5(5):e000919. doi: 10.1136/esmoopen-2020-000919. ESMO Open. 2020. PMID: 33067323 Free PMC article. Review.
Precision Medicine in Lymphoma by Innovative Instrumental Platforms.
Di Paolo A, Arrigoni E, Luci G, Cucchiara F, Danesi R, Galimberti S. Di Paolo A, et al. Among authors: cucchiara f. Front Oncol. 2019 Dec 17;9:1417. doi: 10.3389/fonc.2019.01417. eCollection 2019. Front Oncol. 2019. PMID: 31921674 Free PMC article. Review.
erbB in NSCLC as a molecular target: current evidences and future directions.
Del Re M, Cucchiara F, Petrini I, Fogli S, Passaro A, Crucitta S, Attili I, De Marinis F, Chella A, Danesi R. Del Re M, et al. Among authors: cucchiara f. ESMO Open. 2020 Aug;5(4):e000724. doi: 10.1136/esmoopen-2020-000724. ESMO Open. 2020. PMID: 32820012 Free PMC article. Review.
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Crucitta S, Del Re M, Paolieri F, Bloise F, Sbrana A, Sammarco E, Mercinelli C, Cucchiara F, Fontanelli L, Galli L, Danesi R. Crucitta S, et al. Among authors: cucchiara f. Cancer Chemother Pharmacol. 2020 Oct;86(4):527-533. doi: 10.1007/s00280-020-04133-w. Epub 2020 Sep 18. Cancer Chemother Pharmacol. 2020. PMID: 32945940
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M, Crucitta S, Lorenzini G, De Angelis C, Diodati L, Cavallero D, Bargagna I, Cinacchi P, Fratini B, Salvadori B, Ghilli M, Roncella M, Fontana A, Danesi R, Cucchiara F. Del Re M, et al. Among authors: cucchiara f. Pharmacol Res. 2021 Jan;163:105241. doi: 10.1016/j.phrs.2020.105241. Epub 2020 Oct 10. Pharmacol Res. 2021. PMID: 33049397
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Del Re M, Cucchiara F, Rofi E, Fontanelli L, Petrini I, Gri N, Pasquini G, Rizzo M, Gabelloni M, Belluomini L, Crucitta S, Ciampi R, Frassoldati A, Neri E, Porta C, Danesi R. Del Re M, et al. Among authors: cucchiara f. Cancer Immunol Immunother. 2021 Jun;70(6):1667-1678. doi: 10.1007/s00262-020-02810-6. Epub 2020 Dec 14. Cancer Immunol Immunother. 2021. PMID: 33315149 Free PMC article.
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Vivaldi C, Crucitta S, Catanese S, Cucchiara F, Arrigoni E, Pecora I, Rofi E, Fornaro L, Salani F, Massa V, Vasile E, Morganti R, Danesi R, Del Re M. Vivaldi C, et al. Among authors: cucchiara f. Pharmacogenomics J. 2021 Apr;21(2):233-242. doi: 10.1038/s41397-020-00203-7. Epub 2021 Jan 18. Pharmacogenomics J. 2021. PMID: 33462346
40 results